Inhibrx Biosciences stock falls 1.62 percent on October 5

Published on 10/05/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock was at USD 95.42 on October 5, 2026, while its Q2 loss missed consensus by USD 0.06. Six brokerages set a USD 197.50 average target.

INBX, US45720N1037, Illustration mit AI erstellt.

Inhibrx Biosciences stock (ISIN US45720N1037) was trading at USD 95.42 on Nasdaq on October 5, 2026, down 1.62 percent from the previous close of USD 96.99. The company had filed an updated corporate presentation with the SEC on September 28, 2026, keeping its clinical pipeline at the center of the investment case.

Updated presentation keeps pipeline central

According to the SEC, Inhibrx posted an updated corporate presentation on September 28, 2026, through the Investors section of its website. The filing identifies INBX common stock as registered on the Nasdaq Global Market.

The company describes its platform as focused on engineered biologic medicines for serious diseases with limited treatment options. Its investor materials list pipeline programs including INBRX-106 and ozekibart, while the business remains in the clinical-development phase rather than a commercial revenue phase.

Q2 loss missed the estimate

Inhibrx reported a diluted loss of USD 2.34 per share for Q2 2026, compared with a consensus loss of USD 2.28 per share, a USD 0.06 miss, according to MarketBeat in its October 3, 2026 report. The finance statements show net loss attributable to common shareholders of USD 36.65 million for the quarter ended June 30, 2026.

Cash and cash equivalents stood at USD 133.344 million on June 30, 2026, down from USD 161.657 million on March 31, 2026. Operating cash flow was negative USD 29.917 million in Q2, making cash use a central counterweight to the pipeline opportunity.

Targets remain above the stock

MarketBeat reported a Moderate Buy consensus from six brokerages on October 3, 2026. The average 12-month price target was USD 197.50, with one sell rating, two hold ratings, two buy ratings and one strong-buy rating.

That target is more than twice the October 5 trading price, but the gap reflects the binary nature of clinical-stage biotechnology. The stock's 52-week range was USD 28.16 to USD 155.29, while its market capitalization was USD 1.4 billion and trading volume stood at 29,619 shares as of the October 5 quote.

Inhibrx stock trades near USD 95

Inhibrx Biosciences stock was last at USD 95.42 on Nasdaq on October 5, 2026, at 11:16 a.m. ET, with an intraday range of USD 94.70 to USD 98.00. The negative session move contrasts with the higher analyst targets and leaves clinical progress, cash consumption and regulatory execution as the key valuation variables.